Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study. (PubMed, Int J Clin Oncol) - Oct 15, 2026 - P2 | "These data underscore liso-cel as an effective treatment option with a manageable safety profile for Japanese patients with 2L+ R/R FL. Trial registration number NCT04245839."
Journal • P2 data • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Oncology
|
|
Hideki Goto; Koji Izutsu; Maria Strocchia; Merav Bar; Prachi Ghodke; Rina Nishii; Shinichi Makita; Takanori Teshima; Yuichi Baba
|